Navigation Links
Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
Date:10/31/2011

In this News Digest:

  • Summary of a study being published online Oct. 31, 2011, in the Journal of Clinical Oncology finding that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations -- do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations. These results run counter to a previous study showing a higher risk for these women, and suggest they may not need extra cancer screening and other preventive measures.
  • Quote for attribution to Andrew Seidman, MD, American Society of Clinical Oncology Cancer Communications Committee member and breast cancer specialist.
  • Links to additional information on http://www.Cancer.Net, ASCO's patient Website

A population-based analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations. While these results support most previous evidence regarding risks for non-carriers of BRCA mutations, they run counter to a 2007 study that indicated first-degree relatives (mothers, sisters and daughters) of women with BRCA gene mutations are several times more likely than the general population to develop breast cancer - despite not having the mutation themselves. The new findings suggest that women who test negative for the mutation may not need extra cancer screening and other increased preventive measures.

"This new study gives reassurance to non-carriers that they do not have an increased risk due to the familial mutation, and should be regarded the same as other non-carriers with first-degree relatives who have had breast cancer," said study first author Allison Kurian, MD, assistant professor of medicine and health research and policy at Stanford University School of Medicine. "One strength of the current study is the control women it used as a yardstick for comparing the breast cancer incidence in non-carriers of family-specific mutations. The control women were also relatives of breast cancer patients, but of patients without mutations. This is a more appropriate yardstick than average risk in the general population, since close relatives of all breast cancer patients have somewhat higher than average risks."

Women who inherit a mutation in the BRCA1 or BRCA2 gene carry a 5- to 20-fold higher risk of developing breast or ovarian cancers. First-degree relatives who have not inherited the same familial BRCA mutation have been considered to have a considerably lower risk for breast cancer.

In 2007, a study of women who tested negative for a specific familial BRCA mutation showed they had a 2- to 5-fold increased risk of developing breast cancer; which could be considered comparable to the risk of having a BRCA mutation. According to Kurian, the results raised concerns that non-carriers might require similar screening and preventive measures as their mutation-carrying relatives, such as annual breast MRI and prophylactic surgery, and cast some doubt on the meaning of a negative BRCA test.

Kurian said that the studies had looked at women who were in cancer family clinics and compared their breast cancer risk to that of women in the general population. Women from cancer family clinics were more likely to have intensive screening, and breast cancer risks tend to be higher among close relatives of breast cancer patients than those in the general population.

The investigators took a different approach in this research by studying women with breast cancer in 3,047 families in three population-based cancer registries in Northern California (1,214), Australia (799) and Canada (1,034) through a consortium called the Breast Cancer Family Registry. They found 292 families in which a woman had a BRCA mutation. This is the largest analysis to date of breast cancer risk of non-carriers of family-specific BRCA mutations.

They compared the risk of breast cancer among first-degree relatives of breast cancer patients who did and did not carry a BRCA mutation and found no significant difference. This means that non-carriers of a familial BRCA mutation did not have a markedly elevated risk of developing breast cancer.

The investigators also found that a small percentage of women - 3.4 percent of women in the general populations of Australia, Canada and the U.S. - who are at highest risk for unexplained reasons (reasons other than a BRCA mutation) account for approximately 32 percent of all breast cancer cases, reflecting the wide range of factors that could play a role in breast cancer development. Recent research suggests that many different genetic variants affect breast cancer risk, and that the women at highest risk have inherited many of these variants.

"Earlier reports of higher risk among non-carriers of family-specific BRCA mutations compared to risks in the general population may reflect a comparison of women with and without a family history of breast cancer," noted senior author Alice Whittemore, PhD, professor of epidemiology and biostatistics at Stanford University School of Medicine. "The control group we used - relatives of breast cancer patients in families without a BRCA mutation - was important. The results suggest that women who test negative for their family's BRCA mutation have no greater breast cancer risk than a woman who also has relatives with breast cancer but no family-specific mutation."


'/>"/>
Contact: Nicole Fernandes
nicole.fernandes@asco.org
571-483-1354
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. The freshman 15 is just a myth, nationwide study reveals
2. First-of-its-kind study creates new tool for targeted cancer drug development
3. Study finds community counseling reduced the prevalence of TB on a budget
4. Practice Doesnt Always Make Perfect, Study Suggests
5. NYUCN receives $4.2 million NIH/NIDA grant to study injecting drug users in Kenya
6. NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth
7. Study finds no link between elderly patient activity and hospital falls
8. UT study looks at manual wheelchair use, exercise and calorie burning
9. Study finds specific gene linked to cold sore susceptibility
10. Poorer Countries Have Higher Rates of Stroke, Study Finds
11. NYUCN receives $299 thousand from NCSBN to study patient safety in nursing homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: